Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 32%
Hold 26%
Sell 0%
Strong Sell 5%

Bulls say

Arvinas Inc. demonstrates a positive outlook driven by its innovative therapies targeting disease-causing proteins through its proprietary PROTAC technology. The company’s product candidates, particularly ARV-806, showcase significant pharmacologic advantages over current treatments, exhibiting over 40 times greater potency in reducing KRAS G12D proteins and more than 25 times improved inhibition of 3D spheroid proliferation compared to traditional KRAS inhibitors. Additionally, the potential for enhanced safety and efficacy, particularly in combination regimens, positions Arvinas favorably in the biopharmaceutical landscape, especially with the upcoming approval milestone for vepdeg in June 2025.

Bears say

The financial outlook for Arvinas Inc appears negative due to a combination of decreased projected revenues and challenges in maintaining competitive advantage. Specifically, a significant reduction in peak revenue expectations for vepdeg from $641.2 million to $296.9 million indicates a concerning shift in market penetration and investment viability, highlighting potential risks in the commercialization of their therapies. Furthermore, limited access to capital and funding may hinder the company's operational capabilities, ultimately postponing their path to profitability and cash flow generation.

Arvinas Inc (ARVN) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 19 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.